• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    DCAT Week ’19

    Temperature-Controlled Logistics

    Reducing Pill Burden

    Nasal Drug Delivery

    AI in Pharma: Transforming Data into Drugs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC, Calypso Form Devt./Mfg. Deal

    Quanticate Appoints SVP of Project Delivery

    Alkermes, Clovis Form Cancer Research Collaboration

    APC Expands to U.S. with Opening of MA Facility

    Evotec & HZI Parnter for Novel Antibiotics
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    ACG Capsules Expands in Brazil

    AGC, Calypso Form Devt./Mfg. Deal

    APC Expands to U.S. with Opening of MA Facility

    Catalent Enters Clinical Supply Partnership with Adial

    Catalent Receives P&G Award
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    ACG Capsules Expands in Brazil

    Catalent Receives P&G Award

    GS1 Delivers Lightweight Messaging Standard For Verification of Product Identifiers

    Pelican BioThermal Opens New Network Location

    Reed-Lane Facility Tour
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Quanticate Appoints SVP of Project Delivery

    Alkermes, Clovis Form Cancer Research Collaboration

    APC Expands to U.S. with Opening of MA Facility

    Evotec & HZI Parnter for Novel Antibiotics

    Pii Inks Devt. Deal with Nemus
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Former FDA Senior Executives Join PAREXEL

    Top Global Pharma Company to Implement ValGenesis' VLMS

    WCG, Prudentia Enter Pharmacovigilance Alliance

    ValGenesis VLMS Chosen to Digitize Validation Process

    Serialization Compliance: Understanding the Challenges
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions, Inc.

    Aphena Pharma Solutions, Inc.

    Reed-Lane, Inc.

    Baxter BioPharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Reed-Lane, Inc.

    Alcami

    Federal Equipment Company

    Aphena Pharma Solutions, Inc.

    Ajinomoto Bio-Pharma Services
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    iDD Biotech Receives Second Milestone

    Milstone was initiated after its partner, Genmab, started a Phase I/IIa trial of GEN1029

    Related CONTENT
    • ProBioGen, Pionyr in Devt. and Mfg. Pact
    • Kite, Gadeta Enter Collaboration
    • 09 Gilead Sciences
    • 04 Johnson & Johnson
    • 05 Merck
    12.04.18
    iDD biotech has received a second milestone payment after its partner, Genmab, started a Phase I/IIa trial of GEN1029. 
     
    This potent and innovative combination of two anti-DR5 antibodies was discovered and developed by iDD biotech, who established preclinical proof of concept in solid tumors with unmet medical needs. In March 2015, Genmab signed an agreement to further develop iDD biotech’s DR5-specific antibodies. Genmab developed GEN1029 (HexaBody-DR5/DR5) by introducing an E430G hexamerization-enhancing Fc mutation (HexaBody molecules) in both DR5-specific antibodies, significantly improving DR5 agonist activity of the antibody mixture, resulting in profound tumor cell death in preclinical settings. 
     
    GEN1029 showed strong anti-tumor efficacy in in vitro and in vivo models representing a variety of human solid tumor types. The primary purpose of the clinical trial is to assess the safety of GEN1029 (HexaBody-DR5/DR5) in a mixed population of patients with specified solid tumors. iDD biotech has received a milestone payment of €1 million triggered by the dosing of the fifth patient in the Phase I first-in-human part of the trial. Genmab is responsible for the entire clinical development and commercialization of the drug candidate. This is the second development milestone. 
     
    According to the terms of the agreement, iDD biotech is entitled to receive up to €98 million in future milestone payments and potential royalties for future worldwide sales. 
     
    “This is a validation of our antibody early stage programs and our ability to deliver to patients innovative and best-in-class candidate medicine from our large library of antibodies,” said Hélène Rouquette, chief executive officer and founder of iDD biotech. “We are entering into the very small club of French biotech companies seeing antibodies from their own preclinical research tested in Phase I in human.” 
    Related Searches
    • milestone payment
    • Development
    • Phase I
    • in vivo
    Suggested For You
    Innovent, Hutchison MediPharma in Drug Combo Collaboration Innovent, Hutchison MediPharma in Drug Combo Collaboration
    Aileron, Pfizer in Clinical Collaboration Aileron, Pfizer in Clinical Collaboration
    Immunocore, Genentech Expand Anti-Cancer Alliance Immunocore, Genentech Expand Anti-Cancer Alliance
    F1 Oncology Expands Operations F1 Oncology Expands Operations
    MaSTherCell and Iovance Form Mfg. Agreement MaSTherCell and Iovance Form Mfg. Agreement
    Abzena Signs Cancer Research Pact with Tmunity Therapeutics Abzena Signs Cancer Research Pact with Tmunity Therapeutics
    Fate & ONO Enter Development Partnership Fate & ONO Enter Development Partnership
    bluebird bio, Gritstone Enter Collaboration bluebird bio, Gritstone Enter Collaboration
    Harbour BioMed, Kelun-Biotech Enter Agreement Harbour BioMed, Kelun-Biotech Enter Agreement
    08	AbbVie 08 AbbVie
    05	Merck 05 Merck
    04	Johnson & Johnson 04 Johnson & Johnson
    09	Gilead Sciences 09 Gilead Sciences
    Kite, Gadeta Enter Collaboration Kite, Gadeta Enter Collaboration
    ProBioGen, Pionyr in Devt. and Mfg. Pact ProBioGen, Pionyr in Devt. and Mfg. Pact

    Related Breaking News

    • Breaking News | Collaborations & Alliances | Drug Development | Industry News
      Pii Inks Devt. Deal with Nemus

      Pii Inks Devt. Deal with Nemus

      CDMO to develop dosage formulation for human dosing with NB1111 for glaucoma
      02.20.19

    • Bio News | Collaborations & Alliances | Drug Development | Industry News | Laboratory Testing | R&D
      Evotec & HZI Parnter for Novel Antibiotics

      Evotec & HZI Parnter for Novel Antibiotics

      Research activities will initially be focused on the optimization of cystobactamids
      02.20.19

    • Breaking News | Clinical Trials | Collaborations & Alliances | Drug Development | Industry News

      Gliknik Receives $15M Milestone from Pfizer

      Follows start of Phase 1 trial for Pfizer candidate PF-06755347
      02.20.19


    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      PPD & HLT Enter Development Agreement

      PPD & HLT Enter Development Agreement

      To create data science-driven clinical research solutions in China with the goal of enhancing global drug development
      02.20.19

    • Breaking News | Drug Development | Industry News
      Nestlé Health Licenses Codexis’ CDX-6114

      Nestlé Health Licenses Codexis’ CDX-6114

      Novel, oral enzyme for phenylketonuria is Codexis’ first internally developed biotherapeutic candidate
      02.19.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      SK, Arvelle Sign $530M Deal for Antiepileptic Drug

      SK, Arvelle Sign $530M Deal for Antiepileptic Drug

      Mark Altmeyer named president and chief executive of Arvelle
      02.15.19


    • Breaking News | Collaborations & Alliances | Drug Discovery | Industry News
      Jubilant Biosys, Sanofi Expand Collaboration

      Jubilant Biosys, Sanofi Expand Collaboration

      Collaboration aimed at discovery of small molecule inhibitors targeting neurological disorders
      02.15.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | Laboratory Testing | R&D
      Passage Bio Officially Launches

      Passage Bio Officially Launches

      With $115.5M Series A, to develop AAV-delivered therapeutics to treat rare monogenic CNS diseases
      02.15.19

    • Bio News | Collaborations & Alliances | Drug Development | Industry News | Methods Development | R&D
      Axovant Announces Formation of Arvelle Therapeutics

      Axovant Announces Formation of Arvelle Therapeutics

      Along with the strategic transition of legacy small molecule team into the newly formed company
      02.15.19


    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      AbCellera & Novartis Announce Collaboration

      AbCellera & Novartis Announce Collaboration

      AbCellera to apply technology to advance programs on up to ten targets elected by Novartis
      02.15.19

    • Breaking News | Clinical Trials | Trials & Filings
      SGS to Initiate Malaria Challenge Trial in Belgium

      SGS to Initiate Malaria Challenge Trial in Belgium

      Trial to test the efficacy of MMV’s experimental compound in killing malaria parasites in the liver before they can develop and reach the bloodstream
      02.12.19

    • Breaking News | Clinical Trials | Industry News | Information Technology
      Boehringer, IBM Explore Blockchain Technology in Clinical Trials

      Boehringer, IBM Explore Blockchain Technology in Clinical Trials

      Aims to improve the quality of clinical trial processes and record keeping
      02.12.19

    • Bio News | Clinical Trials | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      NeoTX, MedImmune Announce Clinical Collaboration

      NeoTX, MedImmune Announce Clinical Collaboration

      To support Phase 1b/2 studies investigating ANYARA in combination with AstraZeneca's IMFINZI
      02.11.19

    • Bio News | Collaborations & Alliances | Drug Development | Drug Discovery | Industry News | R&D
      Eton & Sintetica Enter Supply Agreement

      Eton & Sintetica Enter Supply Agreement

      To obtain U.S. marketing rights to two high-volume, near-term product launch candidates.
      02.11.19

    • Bio News | Breaking News | Collaborations & Alliances | Drug Development | Industry News
      3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration

      3SBio, Verseau Establish Immuno-Oncology Devt. Collaboration

      3SBio will fund and conduct antibody development and GMP manufacturing
      02.11.19

    Breaking News
    • AGC, Calypso Form Devt./Mfg. Deal
    • Quanticate Appoints SVP of Project Delivery
    • Alkermes, Clovis Form Cancer Research Collaboration
    • APC Expands to U.S. with Opening of MA Facility
    • Pii Inks Devt. Deal with Nemus
    View Breaking News >
    CURRENT ISSUE

    January/February 2019

    • DCAT Week ’19
    • Temperature-Controlled Logistics
    • Reducing Pill Burden
    • Nasal Drug Delivery
    • AI in Pharma: Transforming Data into Drugs
    • Digitization: Pharma 4.0
    • Serialization Compliance: Understanding the Challenges
    • FDA & Data Integrity
    • Rising Demand for Lyophilized Products
    • Future Trends in the CDMO Space
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • privacy policy
    • term and condition
    • about us
    • contact us

    follow us

    Subscribe

    magazines

    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image
    Image

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login